Prothena Corporation plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRTA research report →
Companywww.prothena.com
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease.
- CEO
- Gene G. Kinney
- IPO
- 2012
- Employees
- 163
- HQ
- Dublin, IE
Price Chart
Valuation
- Market Cap
- $480.33M
- P/E
- -3.26
- P/S
- 8.29
- P/B
- 1.58
- EV/EBITDA
- -1.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 46.85%
- Op Margin
- -217.94%
- Net Margin
- -260.92%
- ROE
- -49.88%
- ROIC
- -39.43%
Growth & Income
- Revenue
- $9.68M · -92.83%
- Net Income
- $-244,092,000 · -99.57%
- EPS
- $-4.53 · -99.56%
- Op Income
- $-184,560,000
- FCF YoY
- -8.89%
Performance & Tape
- 52W High
- $11.80
- 52W Low
- $4.32
- 50D MA
- $10.03
- 200D MA
- $9.54
- Beta
- -0.23
- Avg Volume
- 577.08K
Get TickerSpark's AI analysis on PRTA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | WELCH DANIEL G | other | 27,000 |
| May 15, 26 | Selkoe Dennis J. | other | 27,000 |
| May 15, 26 | Ekman Lars | other | 27,000 |
| May 15, 26 | Dunn William H. Jr. | other | 27,000 |
| May 15, 26 | Cooke Shane | other | 27,000 |
| May 15, 26 | COLLIER RICHARD T | other | 27,000 |
| May 7, 26 | SCULLY WILLIAM P | other | 0 |
| May 7, 26 | SCULLY WILLIAM P | other | 0 |
| May 7, 26 | SCULLY WILLIAM P | other | 0 |
| Apr 10, 26 | Kingston Anne Evans | other | 100,000 |
Our PRTA Coverage
We haven't published any research on PRTA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRTA Report →